These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37492738)

  • 1. Development of an orally bioavailable selective inhibitor of the menin-MLL.
    Zhong HJ; Wang W; Zhou W; Liang JX; Cheng YC; Ma DL; Leung CH
    Genes Dis; 2023 Sep; 10(5):1735-1738. PubMed ID: 37492738
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression.
    Zhang M; Aguilar A; Xu S; Huang L; Chinnaswamy K; Sleger T; Wang B; Gross S; Nicolay BN; Ronseaux S; Harvey K; Wang Y; McEachern D; Kirchhoff PD; Liu Z; Stuckey J; Tron AE; Liu T; Wang S
    J Med Chem; 2021 Jul; 64(14):10333-10349. PubMed ID: 34196551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
    Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA
    Cancer Cell; 2019 Dec; 36(6):660-673.e11. PubMed ID: 31821784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target.
    Brzezinka K; Nevedomskaya E; Lesche R; Haegebarth A; Ter Laak A; Fernández-Montalván AE; Eberspaecher U; Werbeck ND; Moenning U; Siegel S; Haendler B; Eheim AL; Stresemann C
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
    Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
    Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. It's All About MEis: Menin-MLL Inhibition Eradicates NPM1-Mutated and MLL-Rearranged Acute Leukemias in Mice.
    Gundry MC; Goodell MA; Brunetti L
    Cancer Cell; 2020 Mar; 37(3):267-269. PubMed ID: 32183947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of the menin-MLL interaction triggers menin protein degradation via ubiquitin-proteasome pathway.
    Wu Y; Doepner M; Hojnacki T; Feng Z; Katona BW; He X; Ma J; Cao Y; Busino L; Zhou F; Hua X
    Am J Cancer Res; 2019; 9(8):1682-1694. PubMed ID: 31497350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
    Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
    Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.
    Aguilar A; Zheng K; Xu T; Xu S; Huang L; Fernandez-Salas E; Liu L; Bernard D; Harvey KP; Foster C; McEachern D; Stuckey J; Chinnaswamy K; Delproposto J; Kampf JW; Wang S
    J Med Chem; 2019 Jul; 62(13):6015-6034. PubMed ID: 31244110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
    Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
    J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and opportunities in targeting the menin-MLL interaction.
    Cierpicki T; Grembecka J
    Future Med Chem; 2014 Mar; 6(4):447-62. PubMed ID: 24635524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.
    Murai MJ; Chruszcz M; Reddy G; Grembecka J; Cierpicki T
    J Biol Chem; 2011 Sep; 286(36):31742-8. PubMed ID: 21757704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menin-MLL protein-protein interaction inhibitors: a patent review (2014-2021).
    Bai H; Zhang SQ; Lei H; Wang F; Ma M; Xin M
    Expert Opin Ther Pat; 2022 May; 32(5):507-522. PubMed ID: 35202550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.
    Xu S; Aguilar A; Xu T; Zheng K; Huang L; Stuckey J; Chinnaswamy K; Bernard D; Fernández-Salas E; Liu L; Wang M; McEachern D; Przybranowski S; Foster C; Wang S
    Angew Chem Int Ed Engl; 2018 Feb; 57(6):1601-1605. PubMed ID: 29284071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
    Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
    Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
    Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
    Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide.
    Yue L; Du J; Ye F; Chen Z; Li L; Lian F; Zhang B; Zhang Y; Jiang H; Chen K; Li Y; Zhou B; Zhang N; Yang Y; Luo C
    Org Biomol Chem; 2016 Sep; 14(36):8503-19. PubMed ID: 27541268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of menin in hematopoiesis.
    Maillard I; Hess JL
    Adv Exp Med Biol; 2009; 668():51-7. PubMed ID: 20175452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
    Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
    Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.